These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2179525)

  • 21. High frequency of antibodies against recombinant HIV-2 Nef protein in HIV-2-positive and HIV-negative sera.
    Mayer J; Kienzle N; Ulrich R; Hunsmann G; Mueller-Lantzsch N
    AIDS; 1992 May; 6(5):519-20. PubMed ID: 1616664
    [No Abstract]   [Full Text] [Related]  

  • 22. Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients.
    Legrand E; Pellegrin I; Neau D; Pellegrin JL; Ragnaud JM; Dupon M; Guillemain B; Fleury HJ
    AIDS Res Hum Retroviruses; 1997 Nov; 13(16):1383-94. PubMed ID: 9359658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production of a nef-specific monoclonal antibody by the use of a synthetic peptide.
    De Santis R; Anastasi AM; Marcolini S; Valesini G; Pezzella M; Vonesch N; Sturchio E; Mele A
    AIDS Res Hum Retroviruses; 1991 Mar; 7(3):315-21. PubMed ID: 2064828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-nef antibodies and other predictors of disease progression in HIV-1 seropositive injecting drug users.
    Rezza G; Titti F; Pezzotti P; Sernicola L; Lo Caputo S; Angarano G; Lazzarin A; Sinicco A; Rossi GB; Verani P
    J Biol Regul Homeost Agents; 1992; 6(1):15-20. PubMed ID: 1359736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-dependent cellular cytotoxicity via humoral immune epitope of Nef protein expressed on cell surface.
    Yamada T; Watanabe N; Nakamura T; Iwamoto A
    J Immunol; 2004 Feb; 172(4):2401-6. PubMed ID: 14764710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes.
    Ayyavoo V; Kudchodkar S; Ramanathan MP; Le P; Muthumani K; Megalai NM; Dentchev T; Santiago-Barrios L; Mrinalini C; Weiner DB
    AIDS; 2000 Jan; 14(1):1-9. PubMed ID: 10714562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of synthetic peptides for the detection of antibodies against the nef regulating protein in sera of HIV-infected patients.
    Sabatier JM; Clerget-Raslain B; Fontan G; Fenouillet E; Rochat H; Granier C; Gluckman JC; Van Rietschoten J; Montagnier L; Bahraoui E
    AIDS; 1989 Apr; 3(4):215-20. PubMed ID: 2500954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Study of the antigenic structure of human immunodeficiency virus using synthetic peptides].
    Ivanov VS; Chikin LD; Suvorova ZK; Kozhich AT; Ivanov VT
    Bioorg Khim; 1992 Jun; 18(6):784-93. PubMed ID: 1384509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of a novel Nef epitope on the surface of HIV type 1-infected cells.
    Yamada T; Iwamoto A
    AIDS Res Hum Retroviruses; 1999 Jul; 15(11):1001-9. PubMed ID: 10445812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High levels of anti-Nef antibodies may prevent AIDS disease progression in vertically HIV-1-infected infants.
    Corró G; Crudeli CM; Rocco CA; Marino SA; Sen L
    J Int AIDS Soc; 2014; 17(1):18790. PubMed ID: 24560340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epitope mapping of murine monoclonal antibodies against human immunodeficiency virus type 1 Nef.
    Otake K; Fujii Y; Tashiro M; Adachi A; Kitoh J
    Exp Anim; 1997 Jan; 46(1):53-8. PubMed ID: 9027472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection.
    Cheingsong-Popov R; Panagiotidi C; Bowcock S; Aronstam A; Wadsworth J; Weber J
    BMJ; 1991 Jan; 302(6767):23-6. PubMed ID: 1899349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1)--II. Synthetic peptides linked to HIV-1 carrier proteins gag and nef.
    Neurath AR; Strick N; Kolbe H; Kieny MP; Girard M; Jiang S
    Mol Immunol; 1991 Sep; 28(9):965-73. PubMed ID: 1717841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A long-term follow-up of an HIV type 1-infected patient reveals a coincidence of Nef-directed cytotoxic T lymphocyte effectors and high incidence of epitope-deleted variants.
    Singh MK; Janvier G; Calvez V; Coulaud P; Rivière Y
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1265-71. PubMed ID: 11559426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nef and Gag synthetic peptide priming of antibody responses to HIV type 1 antigens in mice and primates.
    Vaslin B; Claverie JM; Benveniste O; Barre-Sinoussi FC; Dormont D
    AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1241-50. PubMed ID: 7531460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
    Thakar MR; Bhonge LS; Lakhashe SK; Shankarkumar U; Sane SS; Kulkarni SS; Mahajan BA; Paranjape RS
    J Infect Dis; 2005 Sep; 192(5):749-59. PubMed ID: 16088824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specificity of anti-Nef antibodies produced in mice immunized with DNA encoding the HIV-1 nef gene product.
    Moureau C; Moynier M; Kavsan V; Montagnier L; Bahraoui E
    Vaccine; 1999 Sep; 18(3-4):333-41. PubMed ID: 10506660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals.
    Cosma A; Nagaraj R; Bühler S; Hinkula J; Busch DH; Sutter G; Goebel FD; Erfle V
    Vaccine; 2003 Dec; 22(1):21-9. PubMed ID: 14604567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 Nef and Vpu Interfere with L-Selectin (CD62L) Cell Surface Expression To Inhibit Adhesion and Signaling in Infected CD4+ T Lymphocytes.
    Vassena L; Giuliani E; Koppensteiner H; Bolduan S; Schindler M; Doria M
    J Virol; 2015 May; 89(10):5687-700. PubMed ID: 25822027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.
    Zheng NN; McElrath MJ; Sow PS; Hawes SE; Diallo-Agne H; Stern JE; Li F; Mesher AL; Robinson AD; Gottlieb GS; Huang Y; Kiviat NB
    J Virol; 2007 Sep; 81(17):9061-71. PubMed ID: 17582003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.